Application of the ANCA Renal Risk Score in the United States: A Single-Center Experience

Disease manifestations of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are diverse and prediction of disease course remains challenging. This includes its kidney involvement, with wide variability in clinical and histologic presentation. Up to 64% to 85% of patients with ANCA-associated vasculitis develop a crescentic glomerulonephritis (GN) with a histologic spectrum from early fibrinoid necrosis to global sclerosis.1,2 Significant strides have been made in the diagnosis and treatment of ANCA-associated vasculitis.